Originally doing business as High Throughput Genomics - renamed in 2011 as HTG Molecular Diagnostics Inc (NASDAQ:HTGM) - the firm is working on molecular-based technology solutions for gene expression profiling, miRNA, siRNA, and mRNA measurement for translational medicine and diagnostic applications. Originally quite active in SBIR (for a publicly traded entity) - but no involvement since 2014 - the company offers ArrayPlate formats to meet the large scale gene expression analysis needs of researchers in pharmaceutical, biotech, and academic research markets. Products include qFix ArrayPlate arrays to measure the groups of commonly studied genes; and qNPA miRNA microarrays for microarray studies. The firm also provides array development and manufacturing services; and CLIA testing services. HTG Edge System is the only automated RNA analysis platform able to deliver extraction-free, multiplexed results on a multitude of biological samples (tissue, blood, serum, cells) in less than 24 hours. The fully automated platform enables the analysis of as many as 47 different genes from minimal specimen with walk-away simplicity, eliminating the tedious extraction, amplification and labeling steps normally associated with RT-PCR. The HTG Edge System simplifies RNA: No RNA extraction required; Multiplex as many as 47 genes per well; All biological sample types, including FFPE, frozen tissue, CTCs, cells, blood, xenografts, and plasma; Walk-away automation; Sample-to-answer in less than 24 hours; Results from as few as 1,000 cells; Open protocols allow user customization.
